Paoli-Calmettes Institute, Endoscopy Unit, Marseille, France.
Inst Paoli Calmettes, Dept Clin Res & Invest, Biostat & Methodolo Unit, Marseille, France; Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Dig Liver Dis. 2020 Jan;52(1):51-56. doi: 10.1016/j.dld.2019.06.025. Epub 2019 Aug 7.
Endoscopic stenting for malignant gastroduodenal outlet obstruction (MGOO) is described as ineffective and not long-lasting despite a few favorable studies. This study aimed to evaluate the clinical outcomes of a large series of patients in a tertiary center.
A single-center retrospective study was performed using data collected from all patients who received palliative duodenal self-expandable metal stents between January 2011 and December 2016. The primary endpoints were patient diet after the first duodenal procedure (Gastric Outlet Obstruction Scoring System, GOOSS) and clinical success. The secondary endpoints were the median patency duration (calculated according to the Kaplan-Meier method) and the cumulative incidence of reintervention.
Two-hundred twenty patients were included. The increase in the GOOSS score was significant (p < 0.001), and the clinical success rate was 86.3%. The median estimated patency duration was 9.0 months [6.5-29.1]. Patients with pancreatic adenocarcinoma had significantly longer patency durations (p = 0.02). The estimated cumulative probability of a second duodenal procedure after 4 months was 13%.
In this large series of patients who underwent duodenal stenting for MGOO, we observed significant changes in GOOSS scores, a relatively long patency duration compared to findings in previous series, and a low probability of subsequent duodenal procedures, primarily due to a low median overall survival time (4 months).
尽管有一些有利的研究,但内镜支架置入术治疗恶性胃十二指肠出口梗阻(MGOO)被描述为无效且持续时间不长。本研究旨在评估一家三级中心的大量患者的临床结果。
使用 2011 年 1 月至 2016 年 12 月期间所有接受姑息性十二指肠自膨式金属支架置入术的患者的数据进行了单中心回顾性研究。主要终点是第一次十二指肠手术后患者的饮食情况(胃出口梗阻评分系统,GOOSS)和临床疗效。次要终点是中位通畅时间(根据 Kaplan-Meier 方法计算)和再次介入的累积发生率。
共纳入 220 例患者。GOOSS 评分的增加具有统计学意义(p<0.001),临床成功率为 86.3%。中位估计通畅时间为 9.0 个月[6.5-29.1]。胰腺腺癌患者的通畅时间明显更长(p=0.02)。4 个月后第二次十二指肠手术的估计累积概率为 13%。
在本项针对 MGOO 行十二指肠支架置入术的大量患者中,我们观察到 GOOSS 评分的显著变化、与以往研究相比相对较长的通畅时间以及随后进行十二指肠手术的概率较低,这主要是由于总生存时间的中位数较低(4 个月)。